NCT02473731View on ClinicalTrials.gov

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 22, 2016

Study Completion Date

October 10, 2016

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

KTN3379

Trial Locations (2)

15213

University of Pittsburgh, Pittsburgh

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT02473731 - A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Biotech Hunter | Biotech Hunter